Transdermal drug delivery: Clinical considerations for the obstetrician-gynecologist

Obstetrics and Gynecology

Volumn 105, Issue 5, 2005, Pages 953-961

  Potts, Russell O ^a   Lobo, Rogerio A ^a  

^a Russ Potts Consulting   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYTAMOXIFEN; ESTRADIOL; ESTROGEN; FATTY ACID ESTER; GESTAGEN; NICOTINE; ORAL CONTRACEPTIVE AGENT; OXYBUTYNIN; TAMOXIFEN;

AMENORRHEA; AREA UNDER THE CURVE; BREAKTHROUGH BLEEDING; BREAST CANCER; BREAST DISEASE; CLINICAL TRIAL; COUGHING; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG METABOLISM; DRUG TRANSPORT; DYSMENORRHEA; ENDOMETRIUM CANCER; GYNECOLOGY; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; LIFESTYLE; MEDICAL LITERATURE; NICOTINE REPLACEMENT THERAPY; NIGHT SWEAT; OBSTETRICS; ORAL CONTRACEPTION; OVERACTIVE BLADDER; PATIENT COMPLIANCE; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SKIN; SKIN MANIFESTATION; SPOTTING; THROAT DISEASE; THROMBOEMBOLISM; URINE INCONTINENCE; VENOUS THROMBOEMBOLISM; XEROSTOMIA;

ADMINISTRATION, CUTANEOUS; AGED; CONTRACEPTIVE AGENTS, FEMALE; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MENOPAUSE; MIDDLE AGED; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SKIN ABSORPTION; URINARY INCONTINENCE, STRESS;

EID: 17644373403     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1097/01.AOG.0000161958.70059.db     Document Type: Review

References (40)

1. Pirot F, Kalia YN, Stinchcomb AL, Keating G, Bunge A, Guy RH. Characterization of the permeability barrier of human skin in vivo. Proc Natl Acad Sci U S A 1997;94:1562-7.
2. Potts RO, Francoeur ML. The influence of stratum corneum morphology on water permeability. J Invest Dermatol 1991;96:495-9.
3. Golden GM, McKie JE, Potts RO. Role of stratum corneum lipid fluidity in transdermal drug flux. J Pharm Sci 1987;76:25-8.
4. Naik A, Kalia YN, Guy RH. Transdermal drug delivery: overcoming the skin’s barrier function. Pharm Sci Technol 2000;3:318-26.
5. Guzek DB, Kennedy AH, McNeill SC, Wakshull E, Potts RO. Transdermal drug transport and metabolism. I. Comparison of in vitro and in vivo results. Pharm Res 1989;6:33-9.
6. Potts RO, Guy RH. Predicting skin permeability. Pharm Res 1992;9:663-9.
7. Guy RH, Potts RO. Penetration of industrial chemicals across the skin: a predictive model. Am J Ind Med 1993;23:711-9.
8. Godsland IF. Biology: risk factor modification by OCs and HRT lipids and lipoproteins. Maturitas 2004;47:299-303.
9. Le Houezec J. Role of nicotine pharmacokinetics in nicotine addiction and nicotine replacement therapy: a review. Int J Tuberc Lung Dis 2003;7:811-9.
10. Schneider NG, Olmstead RE, Franzon MA, Lunell E. The nicotine inhaler: clinical pharmacokinetics and comparison with other nicotine treatments. Clin Pharmacokinet 2001;40:661-84.
11. Benowitz NL, Zevin S, Jacob P III. Sources of variability in nicotine and cotinine levels with use of nicotine nasal spray, transdermal nicotine, and cigarette smoking. Br J Clin Pharmacol 1997;43:259-67.
12. Allen SS, Hatsukami D, Christianson D, Brown S. Effects of transdermal nicotine on craving, withdrawal and premenstrual symptomatology in short-term smoking abstinence during different phases of the menstrual cycle. Nicotine Tob Res 2000;2:231-41.
13. Hajek P, West R, Foulds J, Nilsson F, Burrows S, Meadow A. Randomized comparative trial of nicotine polacrilex, a transdermal patch, nasal spray, and an inhaler. Arch Intern Med 1999;159:2033-8.
14. Croghan GA, Sloan JA, Croghan IT, Novotny P, Hurt RD, DeKrey WL, et al. Comparison of nicotine patch alone versus nicotine nasal spray alone versus a combination for treating smokers: a minimal intervention, randomized multicenter trial in a nonspecialized setting. Nicotine Tob Res 2003;5:181-7.
15. Daughton DM, Heatley SA, Prendergast JJ, Causey D, Knowles M, Rolf CN, et al. Effect of transdermal nicotine delivery as an adjunct to low-intervention smoking cessation therapy: a randomized, placebo-controlled, double-blind study. Arch Intern Med 1991;151:749-52.
16. Appell RA, Chancellor MB, Zobrist RH, Thomas H, Sanders SW. Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects. Mayo Clin Proc 2003;78:696-702.
17. Davila GW, Daugherty CA, Sanders SW. A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. J Urol 2001;166:140-5.
18. Cano A. Compliance to hormone replacement therapy in menopausal women controlled in a third level academic centre. Maturitas 1994;20:91-9.
19. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523-34.
20. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women’s Health Initiative Randomized Trial. JAMA 2003;289:3243-53.
21. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 2004;291:1701-12.
22. Slater CC, Hodis HN, Mack WJ, Shoupe D, Paulson RJ, Stanczyk FZ. Markedly elevated levels of estrone sulfate after long-term oral, but not transdermal, administration of estradiol in postmenopausal women. Menopause 2001;8:200-3.
23. Scarabin PY, Oger E, Plu-Bureau G. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003;362:428-32.
24. Vihma V, Vehkavaara S, Yki-Jarvinen H, Hohtari H, Tikkanen MJ. Differential effects of oral and transdermal estradiol treatment on circulating estradiol fatty acid ester concentrations in postmenopausal women. J Clin Endocrinol Metab 2003;88:588-93.
25. Campagnoli C, Colombo P, De Aloysio D, Gambacciani M, Grazioli I, Nappi C, et al. Positive effects on cardiovascular and breast metabolic markers of oral estradiol and dydrogesterone in comparison with transdermal estradiol and norethisterone acetate. Maturitas 2002;41:299-311.
26. Jensen J, Christiansen C. Effects of smoking on serum lipoproteins and bone mineral content during postmenopausal hormone replacement therapy. Am J Obstet Gynecol 1988;159:820-5.
27. Ginsburg ES, Mello NK, Mendelson JH, Barbieri RL, Teoh SK, Rothman M, et al. Effects of alcohol ingestion on estrogens in postmenopausal women. JAMA 1996;276:1747-51.
28. Ginsburg ES, Walsh BW, Gao X, Gleason RE, Feltmate C, Barbieri RL. The effect of acute ethanol ingestion on estrogen levels in postmenopausal women using transdermal estradiol. J Soc Gynecol Investig 1995;2:26-9.
29. Taggart W, Dandekar K, Ellman H, Notelovitz M. The effect of site of application on the transcutaneous absorption of 17-beta estradiol from a transdermal delivery system (Climara). Menopause 2000;7:364-9.
30. Jarvinen A, Backstrom A, Elfstrom C, Viitanen A. Comparative absorption and variability in absorption of estradiol from a transdermal gel and a novel matrix-type transdermal patch. Maturitas 2001;38:189-96.
31. Huezo CM. Current reversible contraceptive methods: a global perspective. Int J Gynaecol Obstet 1998;62(suppl 1):S3-15.
32. Piccinino LJ, Mosher WD. Trends in contraceptive use in the United States: 1982-1995. Fam Plann Perspect 1998;30:4-10, 46.
33. Trussell J, Vaughan B. Contraceptive failure, method-related discontinuation and resumption of use: results from the 1995 National Survey of Family Growth. Fam Plann Perspect 1999;31:64-72, 93.
34. Rosenberg MJ, Waugh MS, Meehan TE. Use and misuse of oral contraceptives: risk indicators for poor pill taking and discontinuation. Contraception 1995;51:283-8.
35. Fu H, Darroch JE, Haas T, Ranjit N. Contraceptive failure rates: new estimates from the 1995 National Survey of Family Growth. Fam Plann Perspect 1999;31:56-63.
36. Rosenberg MJ, Waugh MS, Burnhill MS. Compliance, counseling and satisfaction with oral contraceptives: a prospective evaluation. Fam Plann Perspect 1998;30:89-92, 104.
37. Potter L, Oakley D, Leon-Wong E, Canamar R. Measuring compliance among oral contraceptive users. Fam Plann Perspect 1996;28:154-8.
38. Audet MC, Moreau M, Koltun WD, Waldbaum AS, Shangold G, Fisher AC, et al. Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive: a randomized controlled trial. JAMA 2001;285:2347-54.
39. Dittrich R, Parker L, Rosen JB, Shangold G, Creasy GW, Fisher AC. Transdermal contraception: evaluation of three transdermal norelgestromin/ethinyl estradiol doses in a randomized, multicenter, dose-response study. Am J Obstet Gynecol 2002;186:15-20.
40. Jordan VC, Dowse LJ. Tamoxifen as an anti-tumour agent: effect on oestrogen binding. J Endocrinol 1976;68:297-303.